Related Experiment Videos
A novel membrane antigen selectively expressed on terminally differentiated human B cells
1First Department of Internal Medicine, School of Medicine, University of Tokushima, Japan.
Blood
|September 15, 1994
Summary
Researchers developed anti-HM1.24, a monoclonal antibody targeting the HM1.24 antigen, a novel marker for mature B cells. This antibody shows promise for multiple myeloma immunotherapy by targeting malignant plasma cells.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Multiple myeloma is a plasma cell malignancy.
- Identifying specific markers for malignant plasma cells is crucial for targeted therapies.
Purpose of the Study:
- To develop a monoclonal antibody targeting a novel antigen expressed on malignant plasma cells.
- To characterize the HM1.24 antigen and its expression patterns.
- To evaluate the potential of anti-HM1.24 for multiple myeloma immunotherapy.
Main Methods:
- Development of a monoclonal antibody (anti-HM1.24) against a human plasma cell line.
- Testing antibody reactivity against various myeloma cell lines and patient samples.
- Immunoprecipitation to identify the antigen's molecular weight and characteristics.
Main Results:
- The anti-HM1.24 antibody specifically recognized the HM1.24 antigen on multiple myeloma cells and mature B cells.
- HM1.24 antigen expression was restricted to terminally differentiated B cells, not found in normal tissues.
- The antigen is a membrane glycoprotein (29-33 kD) with high-affinity binding by the antibody.
Conclusions:
- The HM1.24 antigen is a specific marker for late-stage B-cell maturation.
- Anti-HM1.24 antibody holds potential as a therapeutic target for multiple myeloma and related plasma cell disorders.